Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma - A phase I study

被引:84
作者
Menei, P [1 ]
Jadaud, E
Faisant, N
Boisdron-Celle, M
Michalak, S
Fournier, D
Delhaye, M
Benoit, JP
机构
[1] CHU Angers, Dept Neurosurg, F-49033 Angers 01, France
[2] Univ Angers, INSERM, Angers, France
[3] INSERM, Lab Oncopharmacol, U564, Anti Canc Ctr Paul Papin, Angers, France
[4] CHU Angers, Dept Pathol, F-49033 Angers 01, France
关键词
drug delivery; malignant glioma; 5-fluorouracil; microsphere; radiosensitization; stereotaxy;
D O I
10.1002/cncr.11922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The authors developed a new method of drug delivery into the brain using implantable, biodegradable microspheres. The strategy was evaluated initially to provide localized and sustained delivery of the radiosensitizer 5-fluorouracil (5-FU) after patients underwent surgical resection of malignant glioma. In this study, the microspheres were implanted by stereotaxy into deeply situated and inoperable brain tumors. METHODS. Ten patients with newly diagnosed, inoperable, malignant gliomas were included in the study, and I dose of 5-FU was studied (132 mg). After histologic confirmation, a suspension of poly(D-L lactide-co-glycolide) 5-FU-loaded microspheres was implanted by stereotaxy into the tumor in one or several trajectories with one to seven deposits per trajectory. External beam radiation (59.4 grays) was started before postoperative Day 7. Patients were followed by clinical examination, computed tomography scanning, magnetic resonance imaging, and 5-FU assays in blood and cerebrospinal fluid (CSF). RESULTS. The number of trajectories was adapted to the size and shape of the tumor. Microsphere implantation was tolerated well, except in four patients who received a single trajectory and experienced a transitory worsening of preexisting neurologic symptoms. There were no episodes of edema or hematologic complications. 5-FU was detected in CSF and blood in some patients at very low concentrations. The median overall survival was 40 weeks, with 2 patients who had longer survival (71 weeks and 89 weeks, respectively). CONCLUSIONS. In this study, the authors demonstrated that biodegradable microspheres could be implanted by stereotaxy and were efficient systems for drug delivery into brain tumors. This method may have future applications in the treatment of patients other malignancies. (C) 2003 American Cancer Society.
引用
收藏
页码:405 / 410
页数:6
相关论文
共 39 条
[1]   Development of microspheres for neurological disorders: From basics to clinical applications [J].
Benoit, JP ;
Faisant, N ;
Venier-Julienne, MC ;
Menei, P .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :285-296
[2]   PREPARATION AND CHARACTERIZATION OF 5-FLUOROURACIL-LOADED MICROPARTICLES AS BIODEGRADABLE ANTICANCER DRUG CARRIERS [J].
BOISDRONCELLE, M ;
MENEI, P ;
BENOIT, JP .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (02) :108-114
[3]   PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS [J].
BREM, H ;
PIANTADOSI, S ;
BURGER, PC ;
WALKER, M ;
SELKER, R ;
VICK, NA ;
BLACK, K ;
SISTI, M ;
BREM, S ;
MOHR, G ;
MULLER, P ;
MORAWETZ, R ;
SCHOLD, SC .
LANCET, 1995, 345 (8956) :1008-1012
[4]  
Egilmez Nejat K, 2003, Methods Mol Med, V75, P687
[5]  
EMERICH DF, 2002, PHARM RES, V17, P776
[6]   PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release [J].
Faisant, N ;
Siepmann, J ;
Benoit, JP .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 15 (04) :355-366
[7]  
FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO
[8]  
2-S
[9]   Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats [J].
Fournier, E ;
Passirani, C ;
Montero-Menei, C ;
Colin, N ;
Breton, P ;
Sagodira, S ;
Menei, P ;
Benoit, JP .
CANCER, 2003, 97 (11) :2822-2829
[10]  
Gamelin EC, 1996, CANCER, V77, P441, DOI 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO